25 Results

People

  1. Moskowitz
    Moskowitz
  2. Horwitz
    Horwitz
  3. Kumar
    Kumar
  4. Younes
    Younes
  5. Zelenetz
    Zelenetz
  6. Hamlin
    Hamlin
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Myskowski
    Myskowski
  10. Noy
    Noy

Groups

  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Population Sciences Research Program (18)
  6. Executive Committee, Center for Hematologic Malignancies (9)
  7. Sloan Kettering Institute Postdocs (9)
  8. Survivorship Research (8)
  9. Epidemiology and Biostatistics (7)
  10. Biostatistics Service (6)
  1. "female"
  2. "Hematologic Malignancies, Division of"
  3. "Alison Moskowitz"
Formats
  1. Journal Article (22)
  2. Correspondence (1)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Population Sciences Research Program (18)
  6. Executive Committee, Center for Hematologic Malignancies (9)

More Groups

People
  1. Alison Moskowitz (25)
  2. Steven Horwitz (18)
  3. Anita Kumar (9)
  4. Anas Younes (8)
  5. Andrew Zelenetz (8)
  6. Paul Hamlin (8)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (2)
  5. 2020 (7)
  6. 2019 (1)

More Years

Publications
  1. Blood (5)
  2. Blood Advances (4)
  3. Journal of the American Academy of Dermatology (3)
  4. Leukemia and Lymphoma (3)
  5. Lancet Oncology (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. Mosby Elsevier (3)
  3. Taylor & Francis Group (3)
  4. Elsevier Science, Inc. (2)
  5. AME Publishing Company (1)
  6. American Association for Cancer Research (1)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
    Research Letter

    Stuver, R.; Noy, A.; Vardhana, S. A.; Zelenetz, A. D.; Moskowitz, A. J.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
    Journal Article

    Ruan, J.; Moskowitz, A.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Kotlov, N.; Nos, G.; Sorokina, M.; Maksimov, V.; Sboner, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma
    Correspondence

    Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
    Journal Article

    Horwitz, S.; Zinzani, P. L.; Bagot, M.; Kim, Y. H.; Moskowitz, A. J.; Porcu, P.; Dwyer, K.; Sun, W.; Herr, F. M.; Scarisbrick, J.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Journal Article

    Advani, R. H.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Christian, B. A.; Ansell, S. M.; Moskowitz, C. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center
    Journal Article

    Geller, S.; Lebowitz, E.; Pulitzer, M. P.; Horwitz, S. M.; Moskowitz, A. J.; Dusza, S.; Myskowski, P. L.
    Journal of the American Academy of Dermatology (2020)

    Fulltext@MSK | Save